GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Gross Margin %

Organon (Organon) Gross Margin % : 57.26% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Organon Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Organon's Gross Profit for the three months ended in Dec. 2023 was $915 Mil. Organon's Revenue for the three months ended in Dec. 2023 was $1,598 Mil. Therefore, Organon's Gross Margin % for the quarter that ended in Dec. 2023 was 57.26%.


The historical rank and industry rank for Organon's Gross Margin % or its related term are showing as below:

OGN' s Gross Margin % Range Over the Past 10 Years
Min: 52   Med: 62.53   Max: 70.76
Current: 59.84


During the past 6 years, the highest Gross Margin % of Organon was 70.76%. The lowest was 52.00%. And the median was 62.53%.

OGN's Gross Margin % is ranked better than
72.22% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.765 vs OGN: 59.84

Organon had a gross margin of 57.26% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Organon was 0.80% per year.


Organon Gross Margin % Historical Data

The historical data trend for Organon's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Gross Margin % Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 70.76 67.56 62.21 62.84 59.84

Organon Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.00 62.29 60.20 59.71 57.26

Competitive Comparison of Organon's Gross Margin %

For the Drug Manufacturers - General subindustry, Organon's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Organon's Gross Margin % falls into.



Organon Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Organon's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=3748 / 6263
=(Revenue - Cost of Goods Sold) / Revenue
=(6263 - 2515) / 6263
=59.84 %

Organon's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=915 / 1598
=(Revenue - Cost of Goods Sold) / Revenue
=(1598 - 683) / 1598
=57.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Organon  (NYSE:OGN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Organon had a gross margin of 57.26% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Organon Gross Margin % Related Terms

Thank you for viewing the detailed overview of Organon's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Organon (Organon) Business Description

Traded in Other Exchanges
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.
Executives
Kirke Weaver officer: Gen. Counsel & Corp. Secy. 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman officer: General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco officer: Corporate Controller 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler officer: Chief Commercial Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita officer: Head of Global Business Svcs 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr. officer: Head of Manufacturing 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione officer: Chief Human Resources Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah director 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter officer: Hd of Ext. Affairs and ESG 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan officer: Head of Research & Development 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139